Matching-adjusted indirect comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphoma
This comparison of two BTKis used in the treatment of R/R MCL showed that PFS and OS risk was not statistically different between the treatments; however, acalabrutinib had an improved safety profile compared with ibrutinib.
Authors
- Ling Cai (ORCID: https://orcid.org/0000-0002-8592-5269)
- Jack Roos
- Simon Rule (ORCID: https://orcid.org/0000-0001-8937-6351)
- Bengt Liljas
- Paulo Miranda (ORCID: https://orcid.org/0000-0001-6853-7531)
- Michael L. Wang (ORCID: https://orcid.org/0000-0001-9748-5486)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- AstraZeneca (Brazil) (BR)
- AstraZeneca (Canada) (CA)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-10-26
- DOI
- https://doi.org/10.1080/13696998.2024.2422227
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00